Y-90 radiation for liver cancer not treatable by surgery or ablation
Part of Cancer, Digestive system clinical trials.
This study tests whether a targeted radiation treatment called Y-90 segmentectomy can shrink liver tumors. It is for people with one to three small liver tumors that cannot be removed by surgery or destroyed by heat or cold (ablation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer confirmed by biopsy or scan.
- You have either one tumor between 2 and 5 cm, or two to three tumors each 3 cm or smaller.
- You have not had any prior treatment for these tumors.
- You are not able to have surgery or thermal ablation (a procedure that uses heat or cold to destroy tumors).
- You are at least 22 years old and in generally good health (able to care for yourself and up and about).
- Your liver and kidney function are within certain limits, as measured by routine blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.